AC Immune SA (ACIU)
3.41
-0.10
(-2.85%)
USD |
NASDAQ |
May 16, 16:00
3.40
-0.01
(-0.29%)
After-Hours: 20:00
AC Immune Cash from Financing (Quarterly): -0.7872M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.7872M |
| December 31, 2023 | 45.65M |
| September 30, 2023 | 0.5423M |
| June 30, 2023 | 2.126M |
| March 31, 2023 | -0.1523M |
| December 31, 2022 | -0.174M |
| September 30, 2022 | -0.1462M |
| June 30, 2022 | -0.0994M |
| March 31, 2022 | -0.9917M |
| December 31, 2021 | 31.50M |
| September 30, 2021 | 4.644M |
| June 30, 2021 | -0.0793M |
| March 31, 2021 | 8.521M |
| December 31, 2020 | -0.4835M |
| September 30, 2020 | 0.1261M |
| June 30, 2020 | -0.1126M |
| March 31, 2020 | -0.3865M |
| December 31, 2019 | -0.4236M |
| September 30, 2019 | 0.7715M |
| Date | Value |
|---|---|
| June 30, 2019 | -0.8367M |
| March 31, 2019 | 50.43M |
| December 31, 2018 | 0.1391M |
| September 30, 2018 | 111.53M |
| June 30, 2018 | 0.1441M |
| March 31, 2018 | 0.0011M |
| December 31, 2017 | 0.1266M |
| September 30, 2017 | 0.0562M |
| June 30, 2017 | 0.0635M |
| March 31, 2017 | 0.0289M |
| December 31, 2016 | -3.301M |
| September 30, 2016 | 69.73M |
| June 30, 2016 | 13.93M |
| March 31, 2016 | -0.3805M |
| December 31, 2015 | 28.82M |
| September 30, 2015 | 0.0372M |
| June 30, 2015 | 0.0053M |
| March 31, 2015 | 0.001M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.9917M
Minimum
Mar 2022
45.65M
Maximum
Dec 2023
4.460M
Average
-0.106M
Median
Cash from Financing (Quarterly) Benchmarks
| CRISPR Therapeutics AG | 305.93M |
| Addex Therapeutics Ltd | -0.1643M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | -0.3157M |
| MoonLake Immunotherapeutics | 50.98M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 1.172M |
| Cash from Investing (Quarterly) | -26.96M |
| Free Cash Flow | -48.92M |
| Free Cash Flow Per Share (Quarterly) | 0.0089 |
| Free Cash Flow Yield | -16.14% |